Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/122197
Title: | Pre-diagnostic blood immune markers, incidence and progression of B-cell lymphoma and multiple myeloma: Univariate and functionally informed multivariate analyses |
Author: | Vermeulen, Roel C. H. Saberi Hosnijeh, Fatemeh Bodinier, Barbara Portengen, Lützen Liquet, Benoît Garrido Manriquez, Javiera Lokhorst, Henk Bergdahl, Ingvar A. Kyrtopoulos, Soterios Johansson, Ann-Sofie Georgiadis, Panagiotis Melin, Beatrice S. Palli, Domenico Krogh, Vittorio Panico, Salvatore Sacerdote, Carlotta Tumino, Rosario Vineis, Paolo Castagné, Raphaele Chadeau-Hyam, Marc EnviroGenoMarkers Consortium Botsivali, Maria Chatziioannou, Aristotelis Valavanis, Ioannis Kleinjans, Jos C. S. Kok, Theo M. C. M. de Keun, Hector C. Athersuch, Toby J. Kelly, Rachel S. Lenner, Per Hallmans, Göran Stephanou, Euripides G. Myridakis, Antonis Kogevinas, Manolis Fazzo, Lucia Santis, Marco De Comba, Pietro Bendinelli, Benedetta Kiviranta, Hannu Rantakokko, Panu Airaksinen, Riikka Ruokojarvi, Paivi Gilthorpe, Mark Fleming, Sarah Fleming, Thomas Tu, Yu-Kang Lundh, Thomas Chien, Kuo-Liong Chen, Wei J. Lee, Wen-Chung Kate Hsiao, Chuhsing Kuo, Po-Hsiu Hung, Hung Liao, Shu-Fen |
Keywords: | Limfomes Citoquines Lymphomas Cytokines |
Issue Date: | 18-Apr-2018 |
Publisher: | Wiley |
Abstract: | Recent prospective studies have shown that dysregulation of the immune system may precede the development of B‐cell lymphomas (BCL) in immunocompetent individuals. However, to date, the studies were restricted to a few immune markers, which were considered separately. Using a nested case–control study within two European prospective cohorts, we measured plasma levels of 28 immune markers in samples collected a median of 6 years before diagnosis (range 2.01–15.97) in 268 incident cases of BCL (including multiple myeloma [MM]) and matched controls. Linear mixed models and partial least square analyses were used to analyze the association between levels of immune marker and the incidence of BCL and its main histological subtypes and to investigate potential biomarkers predictive of the time to diagnosis. Linear mixed model analyses identified associations linking lower levels of fibroblast growth factor‐2 (FGF‐2 p = 7.2 × 10−4) and transforming growth factor alpha (TGF‐α, p = 6.5 × 10−5) and BCL incidence. Analyses stratified by histological subtypes identified inverse associations for MM subtype including FGF‐2 (p = 7.8 × 10−7), TGF‐α (p = 4.08 × 10−5), fractalkine (p = 1.12 × 10−3), monocyte chemotactic protein‐3 (p = 1.36 × 10−4), macrophage inflammatory protein 1‐alpha (p = 4.6 × 10−4) and vascular endothelial growth factor (p = 4.23 × 10−5). Our results also provided marginal support for already reported associations between chemokines and diffuse large BCL (DLBCL) and cytokines and chronic lymphocytic leukemia (CLL). Case‐only analyses showed that Granulocyte‐macrophage colony stimulating factor levels were consistently higher closer to diagnosis, which provides further evidence of its role in tumor progression. In conclusion, our study suggests a role of growth‐factors in the incidence of MM and of chemokine and cytokine regulation in DLBCL and CLL. |
Note: | Reproducció del document publicat a: http://dx.doi.org/10.1002/ijc.31536 |
It is part of: | International Journal of Cancer, 2018 |
URI: | http://hdl.handle.net/2445/122197 |
Related resource: | http://dx.doi.org/10.1002/ijc.31536 |
ISSN: | 1097-0215 |
Appears in Collections: | Articles publicats en revistes (ISGlobal) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
ijc.31536.pdf | 1.06 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License